- |||||||||| phenytoin / Generic mfg., lorazepam / Generic mfg.
Review, Journal: The challenges of treating status epilepticus in rural Canada. (Pubmed Central) - Aug 21, 2024
At the same time, Kivalliq experiences routine dramatic changes in light-dark exposure each year to afford unique insights into circannual SE chronobiology in relation to the chief human zeitgeber of sunlight. This shows that challenges may also represent opportunities, such as for existing and emerging technologies to synergistically address enormous treatment gaps to improve SE care for the people of Kivalliq, while providing novel insights that may also help improve SE clinical care around the world.
- |||||||||| lorazepam / Generic mfg., topiramate / Generic mfg.
Long-Term Outcomes of Patients With Cyclic Vomiting Syndrome Treated at an Academic Motility Center (Exhibit Hall E) - Aug 20, 2024 - Abstract #ACG2024ACG_4554;
90% of patients had 0 to 2 ER admissions/hospitalizations over the previous year and 5 patients had 5 to 7 hospitalizations. 25 (81%) patients identified stress as the cause of their CVS, 11 (35%) attributed it to migraine, 6 (19%) were chronic marijuana users, and 6 (19%) had menstrual cycle-triggered relapses.
- |||||||||| Journal: Management of Severe Pain in a Case of Sensory Guillain-Barre Syndrome. (Pubmed Central) - Aug 12, 2024
This regimen, supplemented with gabapentin, proved effective in managing both GBS-associated and treatment-induced pain...Careful monitoring is imperative to mitigate risks associated with potent analgesics. Our experience contributes to the armamentarium for managing GBS-related pain, emphasizing individualized care to improve patient outcomes.
- |||||||||| Rituxan (rituximab) / Roche
Enrollment change, Trial withdrawal: Emesis Control Study in Non-Hodgkin Lymphoma Patients Receiving R-CHOP (clinicaltrials.gov) - Aug 6, 2024
P=N/A, N=0, Withdrawn,
Our experience contributes to the armamentarium for managing GBS-related pain, emphasizing individualized care to improve patient outcomes. N=130 --> 0 | Unknown status --> Withdrawn
- |||||||||| lorazepam / Generic mfg.
Journal: Impact of an alcohol withdrawal screening and treatment protocol for hospitalized patients. (Pubmed Central) - Aug 5, 2024
N=130 --> 0 | Unknown status --> Withdrawn Protocol implementation did not reduce length of stay in patients with AUD but was associated with a significant reduction in total benzodiazepine dose and, when adjusted, a non-statistically significant decrease in progression to delirium tremens in hospitalized patients, after applying Bonferroni adjustment.
- |||||||||| atovaquone/proguanil / Generic mfg., lorazepam / Generic mfg.
SEVERE MALARIA COMPLICATED BY NONCARDIOGENIC PULMONARY EDEMA: WHEN HYPOPARASITEMIA PROVIDES FALSE REASSURANCE (Convention Center Exhibit Hall: Poster Area 3) - Jul 31, 2024 - Abstract #CHEST2024CHEST_5570;
This case highlights the importance of assessing different prognostic markers when treating for malaria in order to provide adequate therapy in a timely manner. Similarly, it warrants being vigilant with volume repletion given high risk of pulmonary edema in setting of increased capillary permeability[3].
- |||||||||| amantadine / Generic mfg.
AMANTADINE AS A SALVAGE THERAPY FOR BENZODIAZEPINE-REFRACTORY CATATONIA IN THE ABSENCE OF ECT (Convention Center Exhibit Hall: Poster Area 2) - Jul 31, 2024 - Abstract #CHEST2024CHEST_5218;
This case offers valuable insights into managing severe catatonia, emphasizing the need for further research to confirm Amantadine's therapeutic role in such instances. Moreover, this success story highlights the urgent need for intensive care specialists to better recognize and understand malignant catatonia, ensuring timely and proper treatment.
- |||||||||| COMPLEXITY OF DIAGNOSIS AND MANAGEMENT OF SILENT SYNDROME (Convention Center Exhibit Hall: Poster Area 2) - Jul 31, 2024 - Abstract #CHEST2024CHEST_5190;
His home medications included Seroquel 300 mg qAM and 800 mg qHS, Lithium 900 mg qHS, Depakote 1500 mg BID, Keppra 1000 mg BID, Benztropine 0.5 mg BID, and Pramipexole 1.5 mg BID...A trial of lorazepam was initiated for suspected catatonia, though no improvement was observed... As clinicians, we must remain vigilant and bring awareness regarding the recognition and management of SILENT and other medication-induced neurological complications.
- |||||||||| lorazepam / Generic mfg., levetiracetam / Generic mfg., epinephrine / Generic mfg.
ICTAL ASYSTOLE: A RARE CASE OF ICTAL BRADYARRYTHMIA (Convention Center Exhibit Hall: Rapid Fire Area 2C) - Jul 31, 2024 - Abstract #CHEST2024CHEST_3247;
There was no pre-existing or baseline cardiac dysfunction, Postulating probable cause of IA to be related to temporal lobe epilepsy itself.This case highlights importance of simultaneous EEG and EKG recording of focal seizures, especially those of temporal lobe origin, which can pick up the rare but potentially life-threatening occurrence of clinically relevant IA. IA can be successfully treated permanently by surgery or drug modulation in ideal candidates, circumventing the need for lifelong intervention like pacemaker.
- |||||||||| A CHALLENGING CASE OF A 4-WEEK-LONG DELIRIUM TREMENS: A THERAPEUTIC DILEMMA! (Convention Center Exhibit Hall: Poster Area 2) - Jul 31, 2024 - Abstract #CHEST2024CHEST_2642;
Clinical mimickers of prolonged DTs (Wernicke's encephalopathy, electrolytes disturbances, other substances withdrawal, particularly benzodiazepines, subdural hematoma, and sepsis) should be investigated in detail and ruled out in cases of refractory DTs. Various classes of sedatives may be necessary to stabilize critically ill patients with unusually prolonged DTs Further studies are needed to define the standard of care management of persistent DTs.
- |||||||||| lorazepam / Generic mfg., levetiracetam / Generic mfg., meropenem / Generic mfg.
OROPHARYNGEAL COMPRESSION FROM CERVICAL SPINE INJURY (Convention Center Exhibit Hall: Poster Area 2) - Jul 31, 2024 - Abstract #CHEST2024CHEST_2582;
Clinicians have to be sensitive to an array of issues (not just neurologic) that can become evident over time. A multidisciplinary approach is often required for optimal outcomes
- |||||||||| Monjuvi (tafasitamab-cxix) / Incyte
DIALYSIS DISEQUILIBRIUM SYNDROME: A RARE ENTITY IN MODERN MEDICINE (Convention Center Exhibit Hall: Poster Area 2) - Jul 31, 2024 - Abstract #CHEST2024CHEST_1328;
The patient was complaining of increased nausea and vomiting, poor appetite and muscle weakness since starting third line Tafasitamab and Revlimid treatment for DLBCL two days back...She was then noted to have new onset tonic-clonic seizures and was given Ativan and Keppra... Despite being extremely rare, dialysis disequilibrium syndrome should always be considered in a patient with neurological manifestations after a session of hemodialysis.
- |||||||||| Observational data, Journal: Use and misuse of psychoactive medicines: a descriptive cross-sectional study in a densely populated region of Portugal. (Pubmed Central) - Jul 31, 2024
Chronic use of PMed was observed in 25%, especially with sertraline and buprenorphine for opioid use disorder (long-term treatment), and lorazepam (short-term treatment)...Risk of abuse was low for BZDR, whilst four opioids had meaningful doctor shopping indicators - fentanyl, opioid use disorder buprenorphine, morphine and hydromorphone...Prevalence of OA use is low, although with higher risk of misuse than BZDR. Concomitant use of several PMed is frequent.
- |||||||||| Review, Journal: Neuropsychiatric Effects Associated with Opioid-Based Management for Palliative Care Patients. (Pubmed Central) - Jul 20, 2024
It is necessary, even lifesaving, to be cognizant of potential neuropsychiatric effects that opioids can have on an individual, especially for those under palliative care. By having an increased understanding and awareness of potential opioid neuropsychiatric effects, patient quality of life can be improved, healthcare system costs can be decreased, and patient outcomes can be met and exceeded.
- |||||||||| lorazepam / Generic mfg.
Review, Journal: Expanding the phenotype of NEDAMSS with a psychiatric perspective: analysis of a new case, and a systematic review of the literature. (Pubmed Central) - Jul 20, 2024
Our case presents improvement in motor symptoms originally attributed to NEDAMSS, after treatment with Lorazepam following diagnosis with catatonia...The clinical presentation of NEDAMSS motor symptoms and catatonia have similarities and thus poses significant challenges to the diagnostic process, with risk of incorrect or delayed treatment. The limited experience and the complex phenotype of NEDAMSS complicates pharmacological treatment and encourages caution, especially with the use of antipsychotic drugs in the presence of possible catatonic symptoms.
- |||||||||| Akineton (biperiden) / Endo, AbbVie, NN1213 / Novo Nordisk
Enrollment closed, Trial completion date, Trial primary completion date: OptiSeDent: Optimization of Procedural Sedation Protocol Used for Dental Care Delivery in People With Mental Disability (clinicaltrials.gov) - Jul 15, 2024
P4, N=40, Active, not recruiting,
Patients with pNVGP had persistent unmet needs. Unknown status --> Active, not recruiting | Trial completion date: Aug 2014 --> Jul 2025 | Trial primary completion date: Aug 2014 --> Jul 2025
- |||||||||| Journal: Identification of Benzodiazepine Use Based on Dried Blood Stains Analysis. (Pubmed Central) - Jun 27, 2024
We splashed blood stains on cotton fabric with different concentrations of the following benzodiazepines: alprazolam, bromazepam, clonazepam, diazepam and lorazepam, which were dried for 96 h and subsequently quantified by high-performance liquid chromatography coupled mass spectrometry (HPLC-MS). Our results show that it is possible to identify several benzodiazepines contained in a cotton fabric blood stain; consequently, this method may add another sample option to the toxicological analysis of biological vestiges found at a crime scene.
- |||||||||| mianserin hydrochloride / Generic mfg.
Enrollment open, Trial completion date, Trial primary completion date, Combination therapy: A Study of Mianserin in Combination With SSRIs in Depression With Sleep Problems (clinicaltrials.gov) - Jun 26, 2024
P4, N=300, Recruiting,
This strategy warrants further investigation. Not yet recruiting --> Recruiting | Trial completion date: Dec 2023 --> Dec 2025 | Trial primary completion date: Dec 2023 --> Dec 2025
- |||||||||| Journal: Potentially Inappropriate Medication Use in Primary Care in Switzerland. (Pubmed Central) - Jun 21, 2024
However, only few drug classes accounted for the majority of all prescriptions that were PIM according to any of the 6 PIM lists, and by considering this manageable number of drug classes, clinicians could essentially comply with all 6 PIM lists. These results raise awareness of the most common PIMs and emphasize the need for careful consideration of their risks and benefits and targeted deprescribing.
- |||||||||| lorazepam / Generic mfg., prochlorperazine maleate / Generic mfg., sumatriptan succinate / Generic mfg.
Assessing the relative utility of two headache "rescue rooms" and their respective treatment protocols () - Jun 18, 2024 - Abstract #AHS2024AHS_329;
An outpatient headache "rescue room" represents an attractive option for patients requiring treatment of acute migraine headache, conveying clinical efficacy, decreased ER utilization, and a high degree of patient satisfaction. Dropderidol IM appears to be a particularly safe, effective and efficient treatment for use in this setting.
- |||||||||| lorazepam / Generic mfg.
Journal: Exploring the Trajectory of Catatonia in Neurodiverse and Neurotypical Pediatric Hospitalizations: A Multicenter Longitudinal Analysis. (Pubmed Central) - Jun 17, 2024
One hundred sixty-four patients were treated with a benzodiazepine, with a median maximum 24-hour dose of 6 mg lorazepam-equivalents, which did not differ for patients with and without NDDs...Administered benzodiazepine dose and ECT treatment were similar for all patients, but neurotypical patients had longer hospitalizations than those with NDDs and had a higher odds of a more favorable clinical response. Research under controlled conditions is needed to optimize and endure equitable catatonia treatment in youth.
- |||||||||| lorazepam / Generic mfg., haloperidol / Generic mfg.
Trial completion date, Metastases: NCI-2018-02438: Haloperidol and Lorazepam in Controlling Symptoms of Persistent Agitated Delirium in Patients With Advanced Cancer Undergoing Palliative Care (clinicaltrials.gov) - Jun 3, 2024
P2/3, N=110, Active, not recruiting,
Dementia, CKD, home SSRI/SRNI and stroke/cerebrovascular disease/injury, and spine injuries are independent predictors by BLR. Trial completion date: May 2025 --> Dec 2025
- |||||||||| lorazepam / Generic mfg., amantadine / Generic mfg.
Journal: Catatonia in patients with dementia: A descriptive study of clinical profiles and treatment response. (Pubmed Central) - May 30, 2024
The findings indicate a frequent co-occurrence of catatonia and dementia, highlighting treatability yet suggesting a potential for resistance to lorazepam, which varies by dementia diagnosis. Investigating the mechanisms underlying this resistance and the variability in treatment response is crucial for developing more precise therapeutic strategies.
- |||||||||| lorazepam / Generic mfg., clonidine / Generic mfg.
Trial completion date, Trial primary completion date: Premedication for Claustrophobic Patients for MRI Scan (clinicaltrials.gov) - May 13, 2024
P=N/A, N=50, Recruiting,
No abstract available Trial completion date: Dec 2023 --> Dec 2024 | Trial primary completion date: Dec 2023 --> Dec 2024
- |||||||||| CHANGE-Rx: frailty, falls, polypharmacy, and inappropriate medication use in a Canadian cohort of people aged 65 and older living with HIV (Poster board: 114) - May 2, 2024 - Abstract #AIDS2024AIDS_1411;
The embargo on all abstracts, including oral abstract, poster exhibition, e-poster and late breakers, will lift on Tuesday, 23 July 2024, at 10:00 am Central European Summer Time (CEST). If an abstract is part of an official AIDS 2024 press conference that occurs before that time, the embargo on that abstract lifts at the start of the official press conference.
- |||||||||| lorazepam / Generic mfg., levetiracetam / Generic mfg.
Journal: Bihemispheric Seizure Without Generalization. (Pubmed Central) - Apr 26, 2024
However, additional Clinical events did not recur after intravenous lorazepam (4
|
